A randomized, placebo-controlled, phase 1 study to evaluate the effects of TAK-063 on ketamine-induced changes in fMRI BOLD signal in healthy subjects
Sign Up to like & getrecommendations! Published in 2019 at "Psychopharmacology"
DOI: 10.1007/s00213-019-05366-1
Abstract: Rationale Phosphodiesterase 10A inhibitor TAK-063 has shown effects that suggest efficacy in schizophrenia treatment. Objective This randomized, double-blind, placebo-controlled, incomplete-crossover study investigated effects of single oral administration of TAK-063 on ketamine-induced changes in blood oxygen… read more here.
Keywords: fmri bold; ketamine induced; bold signal; placebo ... See more keywords
The phosphodiesterase 10A selective inhibitor, TAK-063, induces c-Fos expression in both direct and indirect pathway medium spiny neurons and sub-regions of the medial prefrontal cortex in rats
Sign Up to like & getrecommendations! Published in 2017 at "Neuroscience Research"
DOI: 10.1016/j.neures.2017.06.007
Abstract: TAK-063, a selective phosphodiesterase 10A (PDE10A) inhibitor, produces potent antipsychotic-like and pro-cognitive effects in rodents via balanced activation of striatal direct and indirect pathway medium spiny neurons (MSNs). Brain activity modulation by TAK-063 has been… read more here.
Keywords: cortex; direct indirect; pathway; expression ... See more keywords